Clare Ozawa
Managing Director @ Versant Ventures
San Diego, United States
Clare Ozawa is a Series A investor at Versant Ventures in San Diego focused on Health Care and Biotechnology. Clare Ozawa is based out of San Diego, California, and is the managing director of Versant Ventures. Clare previously worked at Inception Sciences as a strategic business operations manager. Clare Ozawa attended the Stanford University.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 58%
Last updated:
For AI agents: llms.txt
Industries Clare Ozawa invests in
Stages Clare Ozawa invests in
Countries Clare Ozawa invests in
Investment Focus
Industry
- Health Care 6 (50%)
- Biotechnology 6 (50%)
- Pharmaceutical 4 (33%)
- Therapeutics 3 (25%)
- Medical 2 (17%)
Stage
- Series A 7 (58%)
- Series B 4 (33%)
- Series C 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Gate Bioscience
|
Gate Bioscience specializes in a small molecule modality to treat biology’s intractable diseases. | $65M / Series B / Nov 13, 2025 | |
858 Therapeutics
|
858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA. | $50M / Series B / Sep 26, 2024 | |
|
Gate Bioscience
|
Gate Bioscience specializes in a small molecule modality to treat biology’s intractable diseases. | $60M / Series A / Nov 01, 2023 | |
Kate Therapeutics
|
Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases. | $51M / Series A / Jun 08, 2023 | |
|
858 Therapeutics
|
858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA. | $60M / Series A / Sep 21, 2021 | |
Lycia Therapeutics
|
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $70M / Series B / Sep 09, 2021 | |
LENZ Therapeutics
|
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. | $47M / Series A / Jun 17, 2021 | |
Capsida Biotherapeutics
|
Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders. It features a proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the diseased organ. | $50M / Series A / Apr 29, 2021 | |
Contineum Therapeutics
|
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to thenervous system. | $80M / Series C / Feb 11, 2021 | |
|
Lycia Therapeutics
|
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $50M / Series A / Jun 09, 2020 | |
| See all 12 investments → | |||
Co-Investors
About Versant Ventures
Versant Ventures is a healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and officesin Canada, the U.S., and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.
Versant Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Charles Warden
Managing Director
|
|||
|
Clare Ozawa
Managing Director
|
|||
Gianni Gromo
Partner
|
|||
Guido Magni
Partner
|
|||
Max Eisenberg
General Counsel
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Clare Ozawa invest in?
Clare Ozawa invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Clare Ozawa last invest?
The most recent investment recorded for Clare Ozawa closed in Nov 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
